Ask AI
ProCE Banner Activity

Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer

Podcast Episodes

Listen to Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss the new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer.

Released: April 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, nurses, and other HCPs involved in caring for patients with GEA or BTC. Additionally, it aims to empower patients with vital information to actively participate in their treatment decisions, fostering a collaborative approach to their care.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recent practice-changing data from clinical trials of HER2-targeted agents into treatment plans for HER2+ GEA and BTC to improve patient outcomes

  • Develop individualized treatment strategies for HER2+ GEA and BTC based on current and emerging evidence supporting the use of HER2-targeted therapies in this setting

  • Communicate emerging data and ongoing clinical trial opportunities in HER2+ GEA and BTC to educate colleagues and counsel patients, fostering a collaborative environment for decision-making in their treatment journey

  • Identify patients with HER2+ GEA and BTC who could benefit from HER2-targeted therapy

Disclosure

Primary Author

Amit Mahipal, MD, MPH: consultant/advisor/speaker: Astellas, AstraZeneca, Jazz.

Shubham Pant, MD: consultant/advisor/speaker: AskGene, AstraZeneca, BPGBio, Ipsen, Jazz, Janssen, Novartis, Zymeworks; researcher (paid to institution): Arcus, Boehringer Ingelheim, Bristol Myers Squibb, Elicio, Ipsen, Janssen, Lilly, Novartis, Pfizer, Zymeworks; equity: Telperian.